The agreement with the Croatian company Jadran (JGL) to purchase the drug D-Panthenol and a number of gynecology products enables EGIS to offer high-quality products to Russians, which is aimed to support health. By complementing its line of well-known products with new brands, EGIS is confirming their high quality at the global level.
“We have been working in the Russian pharmaceutical market for more than 60 years. Throughout this time, we adhere to the partnership strategy, which is based on the obligation to make the latest methods of treatment and drugs of the highest quality available to many Russians,” commented Istvan Khodas, the CEO of EGIS.
The deal also includes the transfer of rights to the five positions of the popular drug D-Panthenol, which improves the regeneration of damaged skin. In Russia, D-Panthenol is the second largest selling brand in the segment of dexpanthenols. The brand most closely matches the main directions of EGIS business and best complements the existing product range of the company. The decision to expand the product portfolio is due to the traditionally close ties of EGIS with the professional medical community and the trust of Russian patients for the EGIS products.
Deliveries of purchased drugs to Russia began in February 2017.